Clinical trial
A First-in-Human, Ascending-Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single, Subcutaneous Dose of LY3209590
NCT02942914 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A First-in-Human, Ascending-Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single, Subcutaneous Dose of LY3209590
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 20, 2016
- Completion date
- October 18, 2017
- Enrollment
- 80 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.